15d-Prostaglandin J2 Inhibits Inflammatory Hypernociception: Involvement of Peripheral Opioid Receptor
Authors:
- Marcelo H. NapimogaMNMarcelo H. Napimoga
- Guilherme R. SouzaGSGuilherme R. Souza
- Thiago M. CunhaTCThiago M. Cunha
- Luiz F. FerrariLFLuiz F. Ferrari
- Juliana T. Clemente-NapimogaJCJuliana T. Clemente-Napimoga
- Carlos A. ParadaCPCarlos A. Parada
- Waldiceu A. VerriWVWaldiceu A. Verri
- Fernando Q. CunhaFCFernando Q. Cunha
- Sérgio H. FerreiraSFSérgio H. Ferreira
- 1 January 2008
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 324 (1) , 313-321
Abstract
The 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is an endogenous ligand of peroxisome proliferator-activated receptors γ (PPAR-γ) and is now recognized as a potent anti-inflammatory mediator. However, information regarding the influence of 15d-PGJ2 on inflammatory pain is still unknown. In this study, we evaluated the effect of 15d-PGJ2 upon inflammatory hypernociception and the mechanisms involved in this effect. We observed that intraplantar administration of 15d-PGJ2 (30–300 ng/paw) inhibits the mechanical hypernociception induced by both carrageenan (100 μg/paw) and the directly acting hypernociceptive mediator, prostaglandin E2 (PGE2). Moreover, 15d-PGJ2 [100 ng/temporomandibular joint (TMJ)] inhibits formalin-induced TMJ hypernociception. On the other hand, the direct administration of 15d-PGJ2 into the dorsal root ganglion was ineffective in blocking PGE2-induced hypernociception. In addition, the 15d-PGJ2 antinociceptive effect was enhanced by the increase of macrophage population in paw tissue due to local injection of thioglycollate, suggesting the involvement of these cells on the 15d-PGJ2-antinociceptive effect. Moreover, the antinociceptive effect of 15d-PGJ2 was also blocked by naloxone and by the PPAR-γ antagonist 2-chloro-5-nitro-N-phenylbenzamide (GW9662), suggesting the involvement of peripheral opioids and PPAR-γ receptor in the process. Similar to opioids, the 15d-PGJ2 antinociceptive action depends on the nitric oxide/cGMP/protein kinase G channel pathway because it was prevented by the pretreatment with the inhibitors of nitric-oxide synthase (NG-monomethyl-l-arginine acetate), guanylate cyclase]1H-(1,2,4)-oxadiazolo(4,2-α)quinoxalin-1-one[, PKG [indolo[2,3-a]pyrrolo[3,4-c]carbazole aglycone (KT5823)], or with the ATP-sensitive potassium channel blocker glibenclamide. Taken together, these results demonstrate for the first time that 15d-PGJ2 inhibits inflammatory hypernociception via PPAR-γ activation. This effect seems to be dependent on endogenous opioids and local macrophages.Keywords
This publication has 41 references indexed in Scilit:
- Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-α receptor agonist GW7647European Journal of Pharmacology, 2007
- Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-αThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Peripheral Sympathetic Component of the Temporomandibular Joint Inflammatory Pain in RatsThe Journal of Pain, 2006
- Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug development?Pharmacology & Therapeutics, 2006
- PPAR-γ: A nuclear receptor with affinity for cannabinoidsLife Sciences, 2005
- Sexual dimorphism in the antinociception mediated by kappa opioid receptors in the rat temporomandibular jointNeuroscience Letters, 2004
- Tissue Monocytes/Macrophages in InflammationAnesthesiology, 2004
- Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in miceLife Sciences, 2004
- Opposite nociceptive effects of the arginine/NO/cGMP pathway stimulation in dermal and subcutaneous tissuesBritish Journal of Pharmacology, 2003
- The cAMP transduction cascade mediates the PGE2‐induced inhibition of potassium currents in rat sensory neuronesThe Journal of Physiology, 1999